Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986460 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Administration of BMS-986460 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986460 | DRUG | Specified dose on specified days. |
Inclusion Criteria: * Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. * Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening * P...
BMS-986460 is an investigational small molecule being studied for the treatment of metastatic castration-resistant prostate cancer, an advanced form of prostate cancer that has spread beyond the prostate and continues to progress despite androgen deprivation therapy. It is in Phase 1 clinical development and has not been approved for any indication.
BMS-986460 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the Phase 1 clinical program evaluating the compound in metastatic castration-resistant prostate cancer.
BMS-986460 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 program is currently recruiting participants and is designed to assess the compound in patients with metastatic castration-resistant prostate cancer.
BMS-986460 is being evaluated in the Phase 1 trial NCT06067841, titled A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer. The trial is currently recruiting, plans to enroll 140 participants, and is open at sites in the United States, Canada, and France.
The Phase 1 trial NCT06067841 enrolls male participants aged 18 years and older with metastatic castration-resistant prostate cancer. It is an uncontrolled, open-label study that does not include healthy volunteers, and enrollment is limited to patients with the specified condition.